Rosa F W, Wilk A L, Kelsey F O
Teratology. 1986 Jun;33(3):355-64. doi: 10.1002/tera.1420330315.
Despite animal vitamin A congener teratogenicity in animal studies since 1954, striking human findings only arose in 1983 following isotretinoin (ITR) marketing for oral treatment of severe acne. By November 1985, 44 outcomes with central nervous system (CNS), cardioaortic (CV), microtia, facial palsy, micrognathia, cleft palate, and/or thymic aplasia defects, and 33 spontaneous abortions have been reported. The critical period for exposure appears to be two to five weeks postconception, although this is clinically inexact. ITR half life is less than a day, although a teratogenic metabolite, 4-oxo-isoretinoin, has a half life of several days. Seven defect outcomes and one stillbirth have been reported with another congener, etretinate (ETR), used for psoriasis. Three of these had meningomyeloceles. Half life of several months makes levels cumulative. Only one additional defect, which may have occurred by chance, is reported with use stopped before conception (4 months). Other discontinuations 1 to 6 months before conception had 11 normal outcomes and two spontaneous abortions. ITR and ETR dose ranged from 0.5 to 1.5 mg/kg. Normal outcomes are reported both with ITR and ETR, but some of these appear not to have been exposed during the critical period. Less striking defects, abortions, and normal outcomes are less well reported. Because vitamin A analogs are therapeutically important and unplanned outcome not always avoidable, further animal research is needed for better risk/benefits. Megadose vitamin A (retinol) use is widespread, but experience poorly observed. Eighteen suspicious birth defect outcomes have been reported from pregnancies with high dose exposure. Twelve had findings similar to those seen in animals and in human retinoid syndromes, e.g., CNS, CV, microtia, and clefts. Epidemiological controls are lacking to establish human teratogenicity, but based on animal studies and experience with ITR and ETR, avoiding long term megadose Vitamin A use in fertile women is warranted.
尽管自1954年起动物研究就发现动物维生素A同类物具有致畸性,但直到1983年异维甲酸(ITR)用于重度痤疮的口服治疗上市后,才出现显著的人类相关发现。到1985年11月,已报告44例出现中枢神经系统(CNS)、心血管(CV)、小耳畸形、面瘫、小颌畸形、腭裂和/或胸腺发育不全缺陷的病例,以及33例自然流产。暴露的关键时期似乎是受孕后两到五周,不过这在临床上并不精确。ITR的半衰期不到一天,尽管致畸代谢物4-氧代异维甲酸的半衰期为几天。另一种用于治疗银屑病的同类物阿维A酯(ETR)已报告7例缺陷病例和1例死产。其中3例患有脊髓脊膜膨出。数月的半衰期使药物水平会累积。在受孕前停药(4个月)的情况下,仅报告了1例可能是偶然发生的额外缺陷。受孕前1至6个月停药的其他情况有11例正常结局和2例自然流产。ITR和ETR的剂量范围为0.5至1.5毫克/千克。ITR和ETR都有正常结局的报告,但其中一些似乎在关键时期未暴露。不太显著的缺陷、流产和正常结局的报告较少。由于维生素A类似物在治疗上很重要,且意外结局并非总是可以避免的,因此需要进一步开展动物研究以更好地评估风险/益处。大剂量维生素A(视黄醇)的使用很普遍,但相关经验观察不足。高剂量暴露的妊娠已报告18例可疑的出生缺陷结局。其中12例的发现与动物和人类类维生素A综合征中所见相似,例如中枢神经系统、心血管、小耳畸形和腭裂。缺乏流行病学对照来确定人类致畸性,但基于动物研究以及ITR和ETR的使用经验,有必要避免育龄妇女长期大剂量使用维生素A。